Alterity Therapeutics (ASX: ATH) has received positive written feedback from the US Food and Drug Administration (FDA) regarding the clinical pharmacology and non-clinical development elements for its Phase 3 program of ATH434 in Multiple System Atrophy (MSA).
The FDA's feedback, which followed a Type C Meeting, specifically provided alignment on key clinical pharmacology and non-clinical development elements.
This clarity is essential for progressing towards the next stage of clinical trials.
Alterity views this positive outcome as an important step towards initiating its Phase 3 program for ATH434, marking significant regulatory progress.
Path to Phase 3 Trial Design
The next critical regulatory step for Alterity Therapeutics involves an End-of-Phase 2 meeting with the FDA, which is anticipated for mid-year 2026.
This upcoming meeting aims to finalise alignment on Chemistry, Manufacturing, and Controls (CMC) requirements, as well as the comprehensive design of the planned Phase 3 trial.
Previous Phase 2 analyses for ATH434 have indicated a favourable safety profile and reinforced positive efficacy signals in patients with MSA.
Continued Financial Stability and Runway
As of 31 December 2025, Alterity Therapeutics maintained a solid financial position, holding cash and cash equivalents of A$49.2 million.
This robust cash balance was significantly strengthened by an approximate A$20 million capital raise conducted in September 2025.
Directors have assessed that the current cash position is sufficient for planned expenditures over the coming year.
The company is also actively exploring non-dilutive funding pathways to support the substantial costs associated with Phase 3 clinical trials.
Leadership and Governance Update
Alterity Therapeutics recently completed a planned board succession.
This saw the appointment of David Stamler as Managing Director and CEO, and Julian Barbaczy as Non-Executive Chair.
These strategic leadership changes are intended to provide continuity and strengthen governance, aligning with the company's progression into late-stage clinical development.
Further reinforcing its regulatory pathway, Alterity had previously secured Fast Track designation from the FDA for ATH434 in MSA.
Outlook and Key Risks
Alterity Therapeutics has made significant progress towards initiating its Phase 3 program for ATH434 in MSA, bolstered by positive FDA feedback.
While the company maintains a strong cash position and has strengthened its leadership, key risks remain around FDA alignment on CMC and trial design, the translation of Phase 2 efficacy to Phase 3, and securing sufficient funding for the pivotal trials.
Investors should note that the effectiveness of translating Phase 2 outcomes to a pivotal Phase 3 outcome remains uncertain, and operating losses are expanding, highlighting ongoing funding requirements.
